Opinions & Features

Trump, Interest Rates, And Biotech Investing In 2017

December 23, 2016

We are heading into 2017 with a great deal of uncertainty, but if President-elect Trump governs the nation as he said he would – unconventionally and unpredictably – we may experience a significant uptick in market volatility as foreign governments and global markets react to America’s new stance in the world.

Continue Reading

Siemens And Northwell Announce Alliance, Enter Big Data Arms Race

December 1, 2016

In an era where a doctor’s office can generate a terabyte of data easily and toasters can speak to refrigerators, we are in an unprecedented age of information and connectivity.

Continue Reading

After Lilly Bombs, Could Alzheimer’s Become Healthcare’s Trumpshot?

November 30, 2016

If the healthcare industry’s approach to Alzheimer’s disease were a building project, it could best be described as constructing a skyscraper from the top down–possible, yet at best impractical.

Continue Reading

5 Healthcare Questions That Should (But Won’t) Be Asked At The Debate

October 7, 2016

As the election draws closer, issue polls consistently rank health care affordability at or near the top of American voters’ concerns.

Continue Reading

How Mylan And Pfizer Could Cause A Major Biotech Backlash

August 25, 2016

You know you’re in the middle of a crisis when Martin Shkreli defends your pharmaceutical company’s price hikes.

Continue Reading

Brexit Will Be Bad For Pharma

June 25, 2016

In medicine they talk about triage in making quick decisions to save lives. Central bankers and politicians across Europe will be performing financial triage this weekend on the UK and EU.

Continue Reading

Superbug Hearing: Will Congress Pick Up Ali’s Fight Against Sepsis?

June 14, 2016

During his life, Muhammad Ali did many great things for a great many people. But he may still have another contribution to make to the public, or in this case, for the public’s health.

Continue Reading

A Simple Solution To Fixing The Prescription Drug Cost Crisis

June 6, 2016

The U.S. healthcare system isn’t sustainable in its current form with increasing prices, and the disparate approaches to care across states, hospitals, doctors, insurance companies, and income.

Continue Reading

As Sarepta And Valeant Exit Hearings, Biotech Steps Into M&A

May 2, 2016

The last week was a nonstop whirlwind for biotech, so I’ve decided to treat this entry a little differently by commenting on key events and sharing what I’ve been seeing.

Continue Reading

What Weak Earnings At Goldman Sachs And J.P. Morgan Mean For Biotech

April 22, 2016

This week Goldman Sachs announced that its profits fell 60% in a single quarter and blamed a volatile market that’s hit it across business lines.

Continue Reading